| abstract |
The description presents methods for treating or preventing glioblastoma multiforme (GBM), characterized by the expression of O-methylguanine-DNA methyltransferase (MGMT) and / or the methylation status of the MGMT promoter, including the introduction of an effective amount of 1-ethyl-7- (2-methyl-6- ( 1H-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino [2,3-b] pyrazin-2 (1H) -one or its pharmaceutically acceptable salt, stereoisomer or tautomer to the patient. |